Viberzi vs Motegrity
A side-by-side look at two gastrointestinal medications advertised on TV. Informational only — not medical advice.
| US Viberzi | US Motegrity | |
|---|---|---|
| Generic name | eluxadoline | prucalopride |
| Drug class | Mu-Opioid Receptor Agonist | Serotonin-4 Receptor Agonist |
| Treats | Irritable bowel syndrome with diarrhea | Chronic idiopathic constipation |
| Category | Gastrointestinal | Gastrointestinal |
| Manufacturer | AbbVie | Takeda |
| Year approved | 2015 | 2018 |
| FDA warning | Moderate warnings | Moderate warnings |
| Est. TV ad spend | — | — |
| Common side effects | Constipation, Nausea, Abdominal pain, Risk of pancreatitis | Headache, Abdominal pain, Nausea, Diarrhea |
Motegrity
Frequently asked questions
Is Viberzi or Motegrity better?
Neither is universally "better." Viberzi (eluxadoline) and Motegrity (prucalopride) are both used for gastrointestinal, but the right choice depends on your medical history, insurance and your doctor's guidance. This comparison is informational only.
What's the difference between Viberzi and Motegrity?
Viberzi is a Mu-Opioid Receptor Agonist made by AbbVie, while Motegrity is a Serotonin-4 Receptor Agonist made by Takeda. See the table above for a side-by-side breakdown.
Which one spends more on TV ads?
Viberzi has the larger estimated TV advertising budget of the two.